Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2017

Shannon Stott's Biography



Shannon Stott, Assistant Professor, Massachusetts General Hospital & Harvard Medical School

Shannon Stott, Ph.D., is an Assistant Professor in the Department of Medicine at Harvard Medical School and an Assistant in Genetics at the Massachusetts General Hospital Center for Cancer Research. Her laboratory is comprised of bioengineers, physicists and chemists focused on translating technological advances to relevant applications in clinical medicine. Specifically, Shannon is interested in using microfluidics and imaging technologies to create tools that increase understanding of cancer biology and of the metastatic process. In collaboration with the Toner, Haber and Maheswaran laboratories, Shannon has developed microfluidic devices that can isolate extraordinary rare circulating tumor cells (CTCs) from the blood of cancer patients. Her research also includes novel microfluidic devices for extracellular vesicle isolation and molecular characterization with a goal of earlier cancer detection.

Shannon Stott Image

Microfluidics for the Interrogation of Circulating Biomarkers in Glioblastoma Patients

Monday, 20 March 2017 at 17:15

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Clinically, there is a dire need to diagnose and monitor brain tumor recurrence and to detect mutations in real time to guide patient treatment. A blood-based ‘liquid biopsy’ that captures and analyzes both circulating tumor cells (CTCs) and extracellular vesicles (EVs) would be an ideal approach to better predict tumor response in glioblastoma patients without the need for highly invasive brain surgery. Through these blood-on-a-chip assays, we aim to gain a better understanding of when these important tumor derived CTCs and extracellular vesicles are released and how we can exploit their molecular content to better guide patient treatment. Working in partnership with Dr. Brian Nahed at MGH, we have used our microfluidic technologies to isolate CTCs and EVs from the blood of patients with advanced glioblastoma multiforme. In this talk, data will be presented on our technological approach as well as our effort to interrogate their molecular content using next generation RNA sequencing. Through the microfluidic isolation of blood based biomarkers from patients, our goal is to obtain complementary data to the current standard of care to help better guide treatment.


Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers World Congress 2017Circulating Biomarkers World Congress 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com